Background: Ischemia-reperfusion (I/R) models have shown that C-reactive protein (CRP) and immunoglobulin M (IgM) are involved in complement activation. Binding of CRP and IgM to damaged cell membranes initiates complement activation and aggravates I/R injury in various organs. However, the time course of CRP- and IgM-mediated complement activation and the relation to hepatocellular injury and inflammation in liver I/R are unknown. Aim: To evaluate the time course of IgM- and CRP-related complement activation and the relation to hepatocellular injury and inflammation in a hepatic I/R rat model. Methods: Male Wistar rats were allocated to (1) five groups of animals exposed to 60 min of partial ischemia (70%) induced via clamping of the left segmental portal triad, followed by 0, 3, 6, 12 or 24 h of reperfusion (n = 6 in each group); (2) five groups of sham-operated animals with corresponding reperfusion times (n = 5), and (3) a control group sacrificed before ischemia (n = 5). Hepatocellular injury, inflammatory response, rat plasma CRP and IgM levels and immunohistochemical depositions of CRP, IgM and C3 were assessed for each group. Results: Histopathological injury scores of hematoxylin and eosin sections of ischemic liver lobes demonstrated increasing values throughout the reperfusion time with a peak at 12 h. Plasma aminotransferases (alanine aminotransferase and aspartate aminotransferase) significantly increased after 3 h of reperfusion, peaking at 6 h (3,100 ± 800 U/l; p < 0.05). Hepatic neutrophil influx significantly increased from 3 to 6 h of reperfusion (p < 0.05) and demonstrated the highest value at 12 h (1.1 ± 0.2 U/mg of protein). Plasma IL-6 levels in the ischemia groups showed peak values after 6 h of reperfusion, decreasing significantly thereafter (p < 0.05). Plasma CRP values reached highest levels after 3 h of reperfusion (mean 91 ± 5% of control pool), decreasing significantly thereafter. Rat IgM concentrations in plasma did not significantly change throughout the reperfusion time. Immunohistochemical depositions of IgM, CRP and C3 in ischemic lobes demonstrated a similar pattern in time, reaching maximum values at 12 h of reperfusion. The percentages of depositions of CRP and IgM were significantly correlated [r(S) = 0.569; p < 0.001; Spearman test]. The time course of C3 and CRP depositions throughout reperfusion and C3 and IgM staining were significantly similar [r(S) = 0.797 and r(S) = 0.656, respectively; p < 0.0001; ANOVA]. Conclusions: CRP and IgM depositions demonstrate a parallel time course throughout the reperfusion to hepatocellular damage, inflammatory response and activated complement deposition in this rat hepatic I/R model. Furthermore, the time course of CRP and IgM depositions was significantly similar to that of activated complement depositions.

1.
Kim YI: Ischemia-reperfusion injury of the human liver during hepatic resection. J Hepatobiliary Pancreat Surg 2003;10:195-199.
2.
Scoazec JY, Borghi-Scoazec G, Durand F, Bernuau J, Pham BN, Belghiti J, Feldmann G, Degott C: Complement activation after ischemia-reperfusion in human liver allografts: incidence and pathophysiological relevance. Gastroenterology 1997;112:908-918.
3.
Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A: Liver ischemia/reperfusion injury: processes in inflammatory networks - a review. Liver Transpl 2010;16:1016-1032.
4.
Kupiec-Weglinski JW, Busuttil RW: Ischemia and reperfusion injury in liver transplantation. Transplant Proc 2005;37:1653-1656.
5.
Dinant S, Vetelainen RL, Florquin S, van Vliet AK, Van Gulik TM: IL-10 attenuates hepatic I/R injury and promotes hepatocyte proliferation. J Surg Res 2007;141:176-182.
6.
Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
7.
Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS, Poe JC, Tedder TF: Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J Immunol 2005;175:8011-8023.
8.
Pratt JR, Basheer SA, Sacks SH: Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002;8:582-587.
9.
Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM: The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401-409.
10.
Farrar CA, Asgari E, Schwaeble WJ, Sacks SH: Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol 2012;3:341.
11.
Austen WG Jr, Zhang M, Chan R, Friend D, Hechtman HB, Carroll MC, Moore FD Jr: Murine hindlimb reperfusion injury can be initiated by a self-reactive monoclonal IgM. Surgery 2004;136:401-406.
12.
Zhang M, Austen WG Jr, Chiu I, Alicot EM, Hung R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD Jr, Carroll MC: Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2004;101:3886-3891.
13.
Chan RK, Verna N, Afnan J, Zhang M, Ibrahim S, Carroll MC, Moore FD Jr: Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM. Surgery 2006;139:236-243.
14.
Haas MS, Alicot EM, Schuerpf F, Chiu I, Li J, Moore FD, Carroll MC: Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc Res 2010;87:618-627.
15.
Zhang M, Alicot EM, Carroll MC: Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model. Mol Immunol 2008;45:4036-4039.
16.
McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL: Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 2006;211:759-766.
17.
Zhang M, Takahashi K, Alicot EM, Vorup-Jensen T, Kessler B, Thiel S, Jensenius JC, Ezekowitz RA, Moore FD, Carroll MC: Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol 2006;177:4727-4734.
18.
Busche MN, Pavlov V, Takahashi K, Stahl GL: Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol 2009;297:H1853-H1859.
19.
Krijnen PA, Ciurana C, Cramer T, Hazes T, Meijer CJ, Visser CA, Niessen HW, Hack CE: IgM colocalises with complement and C reactive protein in infarcted human myocardium. J Clin Pathol 2005;58:382-388.
20.
Padilla ND, van Vliet AK, Schoots IG, Valls Seron M, Maas MA, Peltenburg EE, de Vries A, Niessen HW, Hack CE, Van Gulik TM: C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 2007;142:722-733.
21.
Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999;190:1733-1740.
22.
Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812.
23.
Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP: Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-1221.
24.
Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ: Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol 1993;264:G801-G809.
25.
Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM: The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401-409.
26.
Lehmann TG, Heger M, Munch S, Kirschfink M, Klar E: In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int 2000;13(suppl 1):S547-S550.
27.
Heijnen BH, Straatsburg IH, Padilla ND, Van Mierlo GJ, Hack CE, Van Gulik TM: Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol 2006;143:15-23.
28.
Straatsburg IH, Boermeester MA, Wolbink GJ, Van Gulik TM, Gouma DJ, Frederiks WM, Hack CE: Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. J Hepatol 2000;32:783-791.
29.
Krawisz JE, Sharon P, Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984;87:1344-1350.
30.
van Veen SQ, Dinant S, van Vliet AK, Van Gulik TM: Alkaline phosphatase reduces hepatic and pulmonary injury in liver ischaemia - reperfusion combined with partial resection. Br J Surg 2006;93:448-456.
31.
Diaz PN, Bleeker WK, Lubbers Y, Rigter GM, Van Mierlo GJ, Daha MR, Hack CE: Rat C-reactive protein activates the autologous complement system. Immunology 2003;109:564-571.
32.
Medgyesi GA, Fust G, Gergely J, Bazin H: Classes and subclasses of rat immunoglobulins: interaction with the complement system and with staphylococcal protein A. Immunochemistry 1978;15:125-129.
33.
Racanelli V, Rehermann B: The liver as an immunological organ. Hepatology 2006;43(suppl 1):S54-S62.
34.
Qin X, Gao B: The complement system in liver diseases. Cell Mol Immunol 2006;3:333-340.
35.
de Beer FC, Baltz ML, Munn EA, Feinstein A, Taylor J, Bruton C, Clamp JR, Pepys MB: Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 1982;45:55-70.
36.
Rassouli M, Sambasivam H, Azadi P, Dell A, Morris HR, Nagpurkar A, Mookerjea S, Murray RK: Derivation of the amino acid sequence of rat C-reactive protein from cDNA cloning with additional studies on the nature of its dimeric component. J Biol Chem 1992;267:2947-2954.
37.
Nunomura W, Takakuwa Y, Higashi T: Changes in serum concentration and mRNA level of rat C-reactive protein. Biochim Biophys Acta 1994;1227:74-78.
38.
Kumar A, Pantarotto RE, Kaufman DB: IgG subclasses and IgM in rats: immunoregulatory effects of cimetidine on serum levels. Comp Immunol Microbiol Infect Dis 1990;13:147-153.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.